{
  "paper": "9c38501a6d5b409e387b7c38492c5e88.txt",
  "words": 869,
  "extractions": {
    "title": {
      "value": "Adeno-associated virus (AAV) gene therapy for spinal muscular atrophy",
      "justification": "This title is specific to the study reported by Hugh McMillan in the Children's Hospital of Eastern Ontario (CHEO) Research Institute regarding the AAV9-mediated gene therapy in spinal muscular atrophy as mentioned in the text.",
      "quote": "Adeno-associated virus (AAV) gene therapy for spinal muscular atrophy\n\nHugh Mcmillan, Children's Hospital of Eastern Ontario (CHEO) Research\nInstitute, Pediatrics, Ontario, Canada"
    },
    "description": "The paper discusses the advances and impacts of AAV9-mediated gene therapies for spinal muscular atrophy (SMA), focusing on several studies including SPR1NT, SMART, and STRONG. The challenges and considerations for AAV9-related side effects are also reviewed.",
    "type": {
      "value": "empirical",
      "justification": "The paper discusses the results of studies like SPR1NT, SMART, and STRONG, indicating that empirical evidence and observations are used to evaluate the AAV9-mediated gene therapies.",
      "quote": "Results of the\nPhase 3, SPR1NT study (NCT03505099) will be highlighted, where\npresymptomatic infants (b 6 wks old), were treated with a single dose of\nintravenous (IV) onasemnogene abeparvovec."
    },
    "primary_research_field": {
      "name": {
        "value": "Gene Therapy",
        "justification": "The primary focus of the paper is on AAV gene therapy, which is a form of gene therapy used to treat spinal muscular atrophy.",
        "quote": "Adeno-associated virus (AAV) gene therapy for spinal muscular atrophy"
      },
      "aliases": [
        "AAV gene therapy",
        "Gene therapy for SMA"
      ]
    },
    "sub_research_fields": [
      {
        "name": {
          "value": "Neurology",
          "justification": "The paper is focused on spinal muscular atrophy, which affects the neurological system, thus making Neurology a relevant sub-field.",
          "quote": "Spinal muscular atrophy (SMA) is a hereditary disorder characterized by the progressive loss of motor neurons with resulting muscle atrophy and weakness."
        },
        "aliases": [
          "SMA treatment",
          "Spinal Muscular Atrophy"
        ]
      }
    ],
    "models": [
      {
        "name": {
          "value": "Onasemnogene Abeparvovec",
          "justification": "The paper discusses several trial studies focusing on Onasemnogene Abeparvovec, which is the AAV9-mediated gene therapy used.",
          "quote": "where\npresymptomatic infants (b 6 wks old), were treated with a single dose of\nintravenous (IV) onasemnogene abeparvovec."
        },
        "aliases": [
          "Zolgensma"
        ],
        "is_contributed": {
          "value": true,
          "justification": "The paper provides empirical research and results regarding the therapy, indicating contribution to the field by discussing its development and evaluation.",
          "quote": "Results of the STRONG study (NCT03381729) will be highlighted where children 6 to 60 months old received a single\nintrathecal (IT) dose of onasemnogene abeparvovec."
        },
        "is_executed": {
          "value": true,
          "justification": "The model is executed in the studies mentioned (SPR1NT, STRONG, and SMART), providing data on its use and effects.",
          "quote": "Results of the\nPhase 3, SPR1NT study (NCT03505099) will be highlighted, where\npresymptomatic infants ... were treated with a single dose of\nintravenous (IV) onasemnogene abeparvovec."
        },
        "is_compared": {
          "value": false,
          "justification": "The paper does not discuss a comparison between Onasemnogene Abeparvovec and other treatments within the text provided.",
          "quote": "AAV9-related side\neffects will be reviewed with a view to discussing vector, disease and\npatient-specific considerations when evaluating potential candidacy for\ngene replacement therapy."
        },
        "referenced_paper_title": {
          "value": "Adeno-associated virus (AAV) gene therapy for spinal muscular atrophy",
          "justification": "The section and studies discussed revolve around the use and implications of Onasemnogene Abeparvovec.",
          "quote": "Adeno-associated virus (AAV) gene therapy for spinal muscular atrophy"
        }
      }
    ],
    "datasets": [],
    "libraries": []
  },
  "usage": {
    "completion_tokens": 866,
    "prompt_tokens": 2585,
    "total_tokens": 3451,
    "completion_tokens_details": null,
    "prompt_tokens_details": null
  }
}